2025-05-28 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the data you provided, formatted for a report.

## Merck & Co Inc (MRK) Stock Analysis

**Ticker:** MRK
**Company Name:** Merck & Co Inc
**Company Overview:** A global pharmaceutical company focused on developing and manufacturing innovative medicines and vaccines.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -0.44%
*   **VOO Cumulative Return:** 83.14%
*   **Absolute Divergence (Current):** -83.6%
*   **Divergence Range:** Max: 23.9%, Min: -85.2%
*   **Relative Divergence (Current):** 1.5%

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO) over the period examined.  The current cumulative return is substantially negative, and the relative divergence suggests that MRK's performance is near the lower end of its historical divergence range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha    | Beta  | Cap(B) |
| :----------- | :------- | :------- | :------- | :---- | :------- |
| 2015-2017  | 5.0%     | 58.4%    | -24.0%   | 0.0   | 108.3  |
| 2016-2018  | 42.0%    | 66.6%    | 24.0%    | 0.1   | 151.6  |
| 2017-2019  | 40.0%    | 66.6%    | 11.0%    | 0.2   | 185.4  |
| 2018-2020  | 19.0%    | 66.6%    | -6.0%    | 0.4   | 172.0  |
| 2019-2021  | -1.0%    | 65.6%    | -55.0%   | 0.5   | 175.1  |
| 2020-2022  | 13.0%    | 69.3%    | 7.0%     | 0.5   | 261.6  |
| 2021-2023  | 35.0%    | 69.3%    | 19.0%    | 0.3   | 264.2  |
| 2022-2024  | -6.0%    | 69.3%    | -23.0%   | 0.3   | 247.7  |
| 2023-2025  | -53.0%   | 70.3%    | -84.0%   | 0.4   | 194.8  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** The CAGR has fluctuated significantly. The most recent period (2023-2025) shows a substantial decline.
*   **MDD (Maximum Drawdown):** The MDD is consistently high, indicating significant volatility and potential for large losses.
*   **Alpha:** Alpha is frequently negative, suggesting that MRK has often underperformed its benchmark on a risk-adjusted basis.
*   **Beta:** Beta values are relatively low, indicating that MRK's price is not strongly correlated with the overall market.
*   **Cap(B) Market Cap:** Market cap has fluctuated, peaking between 2021-2023. The latest value shows a significant decline.

### 2. Recent Price Action

*   **Current Price:** 77.59
*   **Previous Close:** 77.58
*   **Change:** 0.01
*   **5-Day Moving Average:** 77.59
*   **20-Day Moving Average:** 78.88
*   **60-Day Moving Average:** 84.16

**Analysis:**  The stock price has shown minimal change in the last day. The 5-day moving average is almost equal to the current price, the 20-day moving average is slightly above the current price, and the 60-day moving average is significantly higher, suggesting a potential downtrend in the short to medium term.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.37 (Low Risk)
*   **RSI (Relative Strength Index):** 46.59 (Neutral)
*   **PPO (Percentage Price Oscillator):** 0.31 (Neutral)
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (7 shares - Caution - MRI:0.37)
*   **Recent (20-day) Relative Divergence Change:** 1.2 (+)
*   **Expected Return:** -730.8%

**Analysis:**

*   The MRI indicates low market risk, which is contradictory with the Hybrid signal(Caution).
*   The RSI suggests a neutral condition.
*   The PPO is close to zero, indicating a weak trend.
*   The hybrid signal suggests to buy.
*   The recent increase in relative divergence is a slightly positive sign, indicating recent outperformance compared to S&P 500.
*   **Expected Return:** The extremely negative expected return suggests that, based on current models, MRK is projected to significantly underperform the S&P 500 over a long-term (2+ year) investment horizon. This is a significant warning sign.
* The price increase of 0.01 is minimal, so it doesn't represent a significant event.

### 4. Recent News & Significant Events

*   **[2025-05-28]:** Major business developments, regulatory changes, or market events.
*   **[2025-05-27]:** Analysts are discussing recent performance and outlook.
*   **[2025-05-26]:** Notable volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-05-25]:** Market experts highlight both risks and opportunities.

**Analysis:** Recent news suggests that the stock has been influenced by several factors, including business developments, regulatory changes, and market events. Analysts are discussing the company's performance and outlook, and the stock has shown notable volatility. Market experts highlight both risks and opportunities.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출        |
| :--------- | :--- | :---------- |
| 2025-05-02 | 2.01 | 15.53 B$    |
| 2024-11-06 | 1.25 | 16.66 B$    |
| 2024-08-05 | 2.15 | 16.11 B$    |
| 2024-05-03 | 1.88 | 15.78 B$    |
| 2025-05-02 | 1.88 | 15.78 B$    |

**Analysis:**  The EPS and revenue figures have fluctuated over the past few quarters. There is a duplicated data: 2025-05-02.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| :--------- | :--------- | :------------ |
| 2025-03-31 | $15.53B    | 77.98%        |
| 2024-12-31 | $15.62B    | 75.50%        |
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE    |
| :--------- | :--------- | :----- |
| 2025-03-31 | $48.34B    | 10.51% |
| 2024-12-31 | $46.31B    | 8.08%  |
| 2024-09-30 | $44.50B    | 7.09%  |
| 2024-06-30 | $43.58B    | 12.52% |
| 2024-03-31 | $40.36B    | 11.80% |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable.
*   **Profit Margin:** Profit margins have been consistently high.
*   **Equity:** Equity has been increasing steadily.
*   **ROE (Return on Equity):** ROE has fluctuated, but overall shows solid profitability.

### 7. Overall Summary and Considerations

Based on the provided data, Merck & Co Inc (MRK) presents a mixed picture.

*   **Negative Factors:** Significant underperformance relative to the S&P 500, negative expected return, and recent volatility are concerning. The historical Alpha is often negative.
*   **Positive Factors:** High profit margins, growing equity, and a low MRI suggest some underlying financial strength.
*   **Key Considerations:**  The negative expected return should be thoroughly investigated. The news headlines suggest potential near-term catalysts or risks. The consistently high MDD indicates a need for caution due to the stock's volatile nature. The contradictory signals between MRI and Hybrid Signal are very concerning.

**Disclaimer:** This analysis is based solely on the provided data and does not constitute financial advice. Investment decisions should be made after consulting with a qualified financial advisor and conducting thorough due diligence.
